ON123300

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：ON123300	Purity：98% min
CAS NO：1357470-29-1	Solubility：DMSO : 16.67 mg/mL (38.81 mM)
Molecular Formula：C₂₄H₂₇N₇O	Package：Package according to customer requirements
Molecular Weight：429.517	Storage：Store at -20℃

Quality control

Remarks

ON123300 is a potent multikinase inhibitor and may be potential useful for brain tumor chemotherapy. ON123300 strongly inhibits Ark5 and CDK4, as well as growth factor receptor tyrosine kinases such as β-type platelet-derived growth factor receptor (PDGFRβ). ON123300 inhibits U87 glioma cell proliferation with an IC(50) 3.4 ± 0.1 μmol/L. ON123300 exhibits potent activity against mantle cell lymphomas (MCLs) both in vitro and in vivo. ON123300 might be an effective agent in MCL, including ibrutinib-resistant forms of the disease.

Properties:
Density: 1.357g/cm3
Boiling Point: 623.6ºC at 760 mmHg
Flash Point: 330.9ºC
Refractive Index: 1.603

Related Products:

BMS-265246; LDC000067; Ribociclib; SU9516; Purvalanol A; Alvocidib; AZD-5597; Kenpaullone; BS-181; JSH-150; Riviciclib; MK-3903

References

[1]. Divakar SK, et al. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. Leukemia. 2016 Jan;30(1):86-93.

[2]. Perumal D, et al. Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer Res. 2016 Mar 1;76(5):1225-36.

[3]. Zhang X, et al. Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models. Mol Cancer Ther. 2014 May;13(5):1105-16.